Lethal versus non-lethal cancers
Team: PRECISION
Challenge: Distinguish between lethal cancers that need treating, and non-lethal cancers that don't.
We set this challenge in 2015, and team PRECISION was funded to address it. Their funding has come to an end, and we're not accepting new applications.
Please note that the description below reflects the challenge as set by our Scientific Committee in 2015; we understand that there may have been developments in the field between then and now.
If you're interested in a plain language summary of the challenge, you can find it at the bottom of the page.
Context
Current screening methods in breast and prostate cancer pick up cancers at an early stage, but lead to over-diagnosis and subsequent over-treatment.
Paradoxically, we don’t as yet have any tools to accurately diagnose other cancers at an early stage, leading to a high cancer-specific mortality (such as for cancers of the pancreas, brain, lung and oesophagus).
The premise of this challenge is that we need a thorough understanding of features that can distinguish a non-lethal growth from a potentially lethal malignant growth, to allow methods to be developed to specifically detect the cancers that require intervention.
Barriers and opportunities
There are two aspects to this challenge: identifying changes that distinguish a non-lethal from a potentially lethal tumour and then determining how these changes would be detected accurately.
This might include (but would not be limited to) defining what distinguishing materials are shed from tumours into the bloodstream or bodily fluids that could be detected, working out how blood-based markers can be traced to a specific organ and determining how to detect the specific abnormalities that would then require intervention.
Vision and Impact
An advance in tackling this challenge could not only save lives from aggressive cancers by finding them earlier, but also reduce the harm caused by treating people with cancers that will never cause them any problems.
This, in turn, could lead to great improvements in how we screen for cancer, by helping us understand what to do with overdiagnosed cancers.
Plain language summary: Why Lethal versus non-lethal cancers?
Our methods for detecting cancer simply aren’t good enough. We need to detect the disease at an early stage, but the diagnosis needs to be more sensitive and accurate too, otherwise we risk missing cancers that cause serious harm, and over-treating those that won’t.
It’s a hard concept to imagine, but not all of the things we call ‘cancer’ need to be treated. Some ‘cancers’ are temporary changes to cells that will reverse or disappear with time, and others are so slow-growing they’ll never cause any problems.
For some cancers, over-diagnosis leads to unnecessary treatment and avoidable side effects. In others, we desperately need to be able to detect the disease earlier – but do so in a more accurate way.
In lung cancer, for example, X-ray scans can’t distinguish between spots where there is nothing to worry about, or the early stages of an aggressive cancer that needs prompt treatment.
This is a Cancer Grand Challenge that would both save lives and improve quality of life – for millions of people worldwide.